Last reviewed · How we verify
HB1801
HB1801 is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T-cell responses.
HB1801 is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T-cell responses. Used for Advanced solid tumors (Phase 3 development).
At a glance
| Generic name | HB1801 |
|---|---|
| Sponsor | Shanghai JMT-Bio Inc. |
| Drug class | Bispecific antibody |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
HB1801 functions as a bispecific monoclonal antibody designed to target multiple immune regulatory pathways. By binding to two different checkpoint molecules, it aims to overcome tumor immune evasion mechanisms and promote robust T-cell activation and proliferation against cancer cells.
Approved indications
- Advanced solid tumors (Phase 3 development)
Common side effects
Key clinical trials
- A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer (PHASE3)
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (PHASE2)
- HB1801 Combined Treatment of HER2-positive Breast Cancer (PHASE2)
- A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer (PHASE2)
- Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer. (PHASE3)
- A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer (PHASE3)
- A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer (PHASE3)
- Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors. (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HB1801 CI brief — competitive landscape report
- HB1801 updates RSS · CI watch RSS
- Shanghai JMT-Bio Inc. portfolio CI